More than 150 health groups called for Turing Pharmaceuticals to follow through on its promise a month ago to lower the price of Daraprim, the 62-year-old medicine whose price Turing raised 5,000 percent after acquiring it earlier this year.
Daraprim treats toxoplasmosis, a rare parasitic infection that can arise in immunocompromised patients, such as those with AIDS and cancer. It's also often used for pregnant women.
Turing acquired the drug and subsequently raised the price from $13.50 a tablet to $750, saying it would use the proceeds to support research of better treatments for toxoplasmosis. Under intense backlash from doctors groups and then the general public, Turing said it would lower the price to break even or to turn a small profit. That was Sept. 22.
"We ... are concerned that despite a commitment by Turing Pharmaceuticals to lower the price of Daraprim (pyrimethamine) more than a month ago, the price has not been reduced nor have distribution issues been sufficiently addressed," the health groups wrote in a statement Thursday.